SEARCH

SEARCH BY CITATION

References

  • 1
    Bini EJ, Brau N, Currie S, Shen H, Anand BS, Hu KQ, et al. Prospective multicenter study of eligibility for antiviral therapy among 4,084 U.S. veterans with chronic hepatitis C virus infection. Am J Gastroenterol 2005; 100: 1772-1779.
    Direct Link:
  • 2
    Gidding HF, Law MG, Amin J, Macdonald GA, Sasadeusz JJ, Jones TL, et al.; ACHOS Investigator Team. Predictors of deferral of treatment for hepatitis C infection in Australian clinics. Med J Aust 2011; 194: 398-402.
  • 3
    Kanwal F, Hoang T, Spiegel BM, Eisen S, Dominitz JA, Gifford A, et al. Predictors of treatment in patients with chronic hepatitis C infection - role of patient versus nonpatient factors. HEPATOLOGY 2007; 46: 1741-1749.
  • 4
    Kramer JR, Kanwal F, Richardson P, Giordano TP, Petersen LA, El-Serag HB. Importance of patient, provider, and facility predictors of hepatitis C virus treatment in veterans: a national study. Am J Gastroenterol 2011; 106: 483-491.
  • 5
    Lettmeier B, Muhlberger N, Schwarzer R, Sroczynski G, Wright D, Zeuzem S, et al. Market uptake of new antiviral drugs for the treatment of hepatitis C. J Hepatol 2008; 49: 528-536.
  • 6
    National Centre in HIV Epidemiology and Clinical Research (NCHECR). HIV/AIDS, viral hepatitis and sexually transmissible infections in Australia. Annual surveillance report 2009. Sydney, Australia: National Centre in HIV Epidemiology and Clinical Research; 2009.
  • 7
    Volk ML, Tocco R, Saini S, Lok AS. Public health impact of antiviral therapy for hepatitis C in the United States. HEPATOLOGY 2009; 50: 1750-1755.
  • 8
    Grebely J, Bryant J, Hull P, Hopwood M, Lavis Y, Dore GJ, et al. Factors associated with specialist assessment and treatment for hepatitis C virus infection in New South Wales, Australia. J Viral Hepat 2011; 18: e104-e116.
  • 9
    Swan D, Long J, Carr O, Flanagan J, Irish H, Keating S, et al. Barriers to and facilitators of hepatitis C testing, management, and treatment among current and former injecting drug users: a qualitative exploration. AIDS Patient Care STDS 2010; 24: 753-762.
  • 10
    Lally MA, Montstream-Quas SA, Tanaka S, Tedeschi SK, Morrow KM. A qualitative study among injection drug using women in Rhode Island: attitudes toward testing, treatment, and vaccination for hepatitis and HIV. AIDS Patient Care STDS 2008; 22: 53-64.
  • 11
    Doab A, Treloar C, Dore GJ. Knowledge and attitudes about treatment for hepatitis C virus infection and barriers to treatment among current injection drug users in Australia. Clin Infect Dis 2005; 40( suppl 5): S313-S320.
  • 12
    Arora S, Thornton K, Murata G, Deming P, Kalishman S, Dion D, et al. Outcomes of treatment for hepatitis C virus infection by primary care providers. N Engl J Med 2011; 364: 2199-2207.
  • 13
    Jacobson IM, Brown RS Jr, Freilich B, Afdhal N, Kwo PY, Santoro J, et al. Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: a randomized trial. HEPATOLOGY 2007; 46: 971-981.
  • 14
    Rodriguez-Torres M, Jeffers LJ, Sheikh MY, Rossaro L, Ankoma-Sey V, Hamzeh FM, et al. Peginterferon alfa-2a and ribavirin in Latino and non-Latino whites with hepatitis C. N Engl J Med 2009; 360: 257-267.
  • 15
    Hill WD, Butt G, Alvarez M, Krajden M. Capacity enhancement of hepatitis C virus treatment through integrated, community-based care. Can J Gastroenterol 2008; 22: 27-32.